Non-Small Cell Carcinoma

In KRAS G12C-mutant NCI-H23 tumor models, NST-628 enhanced the activity of KRAS G12C inhibition. In vivo, NST-628 at 2 mg/kg once daily or sotorasib at 100 mg/kg once daily slowed NCI-H23 tumor growth… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

The phase II cohort of the CodeBreaK 100 study (NCT03600883) investigated the activity of the KRAS G12C inhibitor sotorasib in previously treated patients with KRAS G12C-mutated non-small cell lung ca… (full text at CIViC)

PMID 34096690 · Skoulidis et al., 2021 · Open in CIViC

In a phase I trial, patients with solid tumor harboring KRAS G12C mutation were enrolled. Five out of ten patients with NSCLC showed partial response in this study.

PMID 31239544 · Lindsay et al., 2019 · Open in CIViC

In a phase1 trial, patients with advanced solid tumor harboring KRAS G12C mutation were treated selective KRAS G12C inhibitor AMG 510. Among the 10 patients with non-small cell lung carcinoma, 4 patie… (full text at CIViC)

Open in CIViC

In a dose escalation study (NCT03600883) of AMG 510 (sotorasib) treatment, four KRAS G12C mutant lung cancer patients were treated with 180 mg (n=3) or 360 mg (n=1) doses. Objective responses were see… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to inhibit p-ERK a… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

Combination of the PAK4 inhibitor KPT9274 and KRASG12C inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) shows remarkably enhanced anti… (full text at CIViC)

PMID 37703579 · Khan et al., 2023 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumors and improved the anti-tumor efficacy of chemotherapy and targeted agents. AMG 510 was shown to cause synergist… (full text at CIViC)

PMID 31666701 · Canon et al., 2019 · Open in CIViC

In preclinical experiments using the KRAS G12C mutant NSCLC cell line NCI-H358, combination AZD0364 and selumetinib treatment showed synergistic effect as defined by a Loewe score >=5, as well as stro… (full text at CIViC)

PMID 33273059 · Flemington et al., 2021 · Open in CIViC

A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC)

PMID 23524406 · Rudin et al., 2013 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

A 45-year old male (heavy smoker) presented with stage IV NSCLC (moderately differentiated adenocarcinoma. Sanger sequencing revealed a MET exon 14 splice site mutation (c.2888_3028del) and KRAS G12D … (full text at CIViC)

PMID 27257131 · Liu et al., 2016 · Open in CIViC

Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC)

PMID 19966866 · Liang et al., 2010 · Open in CIViC

In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201).

PMID 15696205 · Pao et al., 2005 · Open in CIViC

In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas… (full text at CIViC)

PMID 16043828 · Eberhard et al., 2005 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

In an in vitro study, the A549 cell line, which harbors the KRAS G12S mutation, was found to have insensitivity to dasatinib treatment (IC50: 7.4 uM). In in vivo experiments, KRAS G12S expressing A549… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas… (full text at CIViC)

PMID 16043828 · Eberhard et al., 2005 · Open in CIViC

Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC. Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12… (full text at CIViC)

PMID 26372703 · Renaud et al., 2015 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient harbored KRAS G12V co-mutation … (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas… (full text at CIViC)

PMID 16043828 · Eberhard et al., 2005 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas… (full text at CIViC)

PMID 16043828 · Eberhard et al., 2005 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

In a clinical study including 148 patients expressing KRAS mutants, low expression of KRAS4A is significantly associated with decreased OS (p = 2.72 x 10^-3) and low proportion of KRAS4A is also signi… (full text at CIViC)

PMID 29504894 · Yang et al., 2018 · Open in CIViC

In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).

PMID 22810899 · Johnson et al., 2013 · Open in CIViC

Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease … (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC